Danica Pension Livsforsikringsaktieselskab Makes New Investment in McKesson Corporation $MCK

Danica Pension Livsforsikringsaktieselskab acquired a new stake in McKesson Corporation (NYSE:MCK) during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 175,204 shares of the company’s stock, valued at approximately $135,352,000. McKesson accounts for approximately 2.1% of Danica Pension Livsforsikringsaktieselskab’s holdings, making the stock its 17th largest holding.

Other hedge funds also recently made changes to their positions in the company. Obsidian Personal Planning Solutions LLC increased its holdings in shares of McKesson by 2.9% during the 3rd quarter. Obsidian Personal Planning Solutions LLC now owns 426 shares of the company’s stock worth $346,000 after acquiring an additional 12 shares during the last quarter. IAM Advisory LLC lifted its holdings in McKesson by 0.3% during the 3rd quarter. IAM Advisory LLC now owns 3,908 shares of the company’s stock valued at $3,019,000 after purchasing an additional 13 shares during the last quarter. PDS Planning Inc lifted its holdings in McKesson by 1.1% during the 3rd quarter. PDS Planning Inc now owns 1,209 shares of the company’s stock valued at $934,000 after purchasing an additional 13 shares during the last quarter. Berkshire Asset Management LLC PA boosted its position in McKesson by 4.6% during the third quarter. Berkshire Asset Management LLC PA now owns 294 shares of the company’s stock worth $227,000 after purchasing an additional 13 shares during the period. Finally, Goldstein Advisors LLC boosted its position in McKesson by 4.4% during the third quarter. Goldstein Advisors LLC now owns 334 shares of the company’s stock worth $258,000 after purchasing an additional 14 shares during the period. 85.07% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on MCK. Raymond James Financial set a $970.00 price objective on shares of McKesson in a research report on Thursday, March 5th. Mizuho lifted their target price on shares of McKesson from $880.00 to $885.00 and gave the stock a “neutral” rating in a report on Thursday, February 5th. TD Cowen upped their price target on shares of McKesson from $1,000.00 to $1,012.00 and gave the company a “buy” rating in a research note on Thursday, February 5th. Leerink Partners reissued an “outperform” rating and issued a $1,085.00 price target on shares of McKesson in a report on Thursday, March 5th. Finally, Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of McKesson in a research report on Wednesday, December 10th. Thirteen research analysts have rated the stock with a Buy rating and four have issued a Hold rating to the stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $960.93.

Insider Activity at McKesson

In other news, EVP Leann B. Smith sold 190 shares of McKesson stock in a transaction that occurred on Tuesday, February 17th. The shares were sold at an average price of $945.00, for a total value of $179,550.00. Following the completion of the sale, the executive vice president directly owned 2,989 shares in the company, valued at approximately $2,824,605. The trade was a 5.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, EVP Michele Lau sold 2,725 shares of the business’s stock in a transaction that occurred on Monday, March 2nd. The shares were sold at an average price of $990.00, for a total value of $2,697,750.00. Following the completion of the sale, the executive vice president owned 3,247 shares of the company’s stock, valued at approximately $3,214,530. This trade represents a 45.63% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders sold 3,868 shares of company stock valued at $3,743,820. 0.08% of the stock is currently owned by company insiders.

McKesson Stock Performance

MCK opened at $942.57 on Wednesday. The stock has a fifty day moving average of $898.61 and a 200-day moving average of $830.00. The company has a market capitalization of $115.45 billion, a P/E ratio of 27.11, a P/E/G ratio of 1.52 and a beta of 0.38. McKesson Corporation has a fifty-two week low of $637.00 and a fifty-two week high of $999.00.

McKesson (NYSE:MCK) last released its quarterly earnings results on Wednesday, February 4th. The company reported $9.34 EPS for the quarter, beating the consensus estimate of $9.19 by $0.15. McKesson had a net margin of 1.09% and a negative return on equity of 338.97%. The business had revenue of $106.16 billion for the quarter, compared to the consensus estimate of $105.98 billion. During the same period in the prior year, the company posted $8.03 earnings per share. McKesson’s revenue was up 11.4% compared to the same quarter last year. McKesson has set its FY 2026 guidance at 38.800-39.200 EPS. On average, equities research analysts predict that McKesson Corporation will post 32.77 earnings per share for the current fiscal year.

McKesson Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 1st. Stockholders of record on Monday, March 2nd will be issued a dividend of $0.82 per share. The ex-dividend date of this dividend is Monday, March 2nd. This represents a $3.28 annualized dividend and a dividend yield of 0.3%. McKesson’s dividend payout ratio (DPR) is currently 9.43%.

About McKesson

McKesson Corporation (NYSE: MCK) is a global healthcare services and distribution company that supplies pharmaceuticals, medical-surgical products and health care technology solutions. Founded in 1833 and headquartered in Irving, Texas, McKesson operates across the drug distribution and healthcare services value chain, connecting manufacturers, pharmacies, hospitals and health systems to help manage the movement of medicines and clinical supplies.

The company’s core activities include pharmaceutical wholesale distribution and logistics, specialty pharmacy services, and the provision of medical-surgical supplies to acute and non-acute care providers.